Pittsburgh, PA (PRWEB) June 25, 2012
Novum Pharmaceutical Research Services has announced that Keith Gallicano, PhD has joined its executive team as Vice President, Scientific Affairs.
Dr. Gallicano has 24 years of diverse experience working in the pharmaceutical field, including various positions in government (Health Canada), academia (University of Ottawa, University of British Columbia), the pharmaceutical manufacturing and CRO service industries His areas of expertise include pharmacokinetics, biopharmaceutics, biostatistics, bioanalytical and clinical trial design, including bioequivalence, drug-drug interaction and phase I and II drug development studies. He has a Ph.D. in Chemistry from the University of British Columbia. He has published extensively in and served on editorial advisory boards of peer-reviewed journals. His earned awards include the 2000 Ontario HIV Treatment Network Career Scientist, the 1998 Canadian Foundation for Innovation Award, and the 1996 Schering national award for best clinical pharmacokinetic project of the Canadian Pharmacy Residency Program.
Chris Hendy Ph.D., President and CEO of Novum, said “We are very excited to have Keith join the Novum team. Scientists of Keith's caliber are hard to come by and we feel he will immediately to bring a new dimension of scientific expertise, allowing us to further widen our service offerings to current and new clients.”
Dr. Gallicano, who most recently served as Director of Biopharmaceutics for Watson Laboratories, Inc., said “I have worked with the Novum team many times in my career and I have always been impressed with their commitment to quality science. This opportunity will allow me to expand my involvement in the design, analysis and reporting of innovative clinical science related to both generic and new drug development.”
About Novum PRS
Novum is a contract research organization ("CRO") that provides clinical research, data management, statistical and reporting services to the pharmaceutical and related industries. Founded in 1972 it operates Phase I research facilities with a total of 550 beds in three USA locations. Novum’s expanding clinical trials management group, currently focuses on performing Phase II through IV clinical equivalence endpoint studies requiring large patient populations. Visit http://www.novumprs.com for more information.